vorinostat

Overview

Vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), is a hydroxamate-based histone deacetylase inhibitor (HDACi) used in biomedical research and therapy development as an epigenetic modulator. By inhibiting histone deacetylases, vorinostat alters chromatin structure and gene expression, which can affect cell-cycle control, apoptosis, differentiation, immune signaling, and stress-response pathways. It has been studied particularly in oncology and transplant medicine, where modulation of tumor cell survival and immune function may be therapeutically useful.

In recent research, vorinostat has been investigated not only as a direct anticancer agent but also as a component of combination strategies. These studies have explored its effects on pathways involving STAT3 signaling, immunogenic cell death, autophagy, apoptosis, and tissue remodeling, as well as its potential to influence graft-versus-host disease and post-transplant cognitive outcomes. Its pharmacologic profile is also being reconsidered in light of evidence that some anticancer effects of SAHA may persist even when canonical HDAC inhibition is altered, suggesting additional mechanisms beyond histone deacetylase blockade.

Focus of Latest Publications

Recent publications have examined vorinostat across several disease models and therapeutic contexts, with a strong emphasis on cancer biology and epigenetic therapy.

In triple-negative breast cancer, SAHA was studied for its ability to induce immunogenic cell death (ICD) in MDA-MB-231 and MDA-MB-468 cell lines, with combination testing against a SOCS3 peptidomimetic, KIRCONG chim PEG, designed to inhibit STAT3 phosphorylation. The work linked vorinostat’s activity to suppression of pSTAT3 and suggested that functional replacement of SOCS3 enhanced the efficacy of SAHA. This places vorinostat within a broader immuno-epigenetic framework, where its effects may intersect with the JAK2/STAT3 signaling pathway and downstream inflammatory or survival programs.

A separate study reported that chemical manipulation of SAHA could abolish its HDAC-inhibiting activity without eliminating anticancer effects in an allograft colon cancer mouse model. This finding is important because it challenges the assumption that histone deacetylase enzyme inhibition is the sole determinant of vorinostat’s antitumor activity. The study supports the idea that SAHA may retain biologic activity through mechanisms independent of direct HDAC blockade.

Vorinostat was also investigated in a murine infantile hemangioma (IH) model, where pan-HDAC inhibition significantly suppressed in vivo vasculogenesis. This suggests a role for SAHA in reprogramming stem cell fate and limiting abnormal vascular development. The study broadens the relevance of vorinostat beyond malignancy to include vascular proliferative disorders.

In transplant medicine, a clinical study evaluated cognitive functioning in vorinostat-treated pediatric and young adult patients during the first 180 days after hematopoietic stem cell transplant. The publication notes prior evidence that HDAC inhibitors such as vorinostat may reduce graft-versus-host disease (GVHD) in allogeneic transplant recipients and may also mitigate some post-transplant cognitive changes seen in adults. In this context, vorinostat is being assessed as part of supportive care and immune modulation after transplantation.

Additional preclinical work has explored vorinostat in metabolic and cardiovascular disease models. In a diabetic cardiomyopathy rat model, SAHA was compared with dapagliflozin, an SGLT2 inhibitor, and showed comparatively greater effects in preserving gap junction integrity and attenuating disease development. The study suggested possible antioxidant and epigenetic mechanisms, with the caveat that the findings were limited to a single-dose experimental model. This work also linked SAHA to changes in Cx43 gene expression, highlighting a potential role in cardiac remodeling under diabetic conditions.

Vorinostat has also been incorporated into drug-delivery and combination-therapy research. A nanotherapeutic approach using esterase-activatable dimeric HDAC inhibitor constructs emphasized that hydroxamate-based HDAC inhibitors like vorinostat have epigenetic therapeutic potential but are limited by poor bioavailability and rapid clearance. This line of work aims to improve pharmacologic performance while preserving HDAC-targeted activity.

Finally, combination studies have examined vorinostat with natural products and other anticancer agents. Nobiletin was reported to synergize with vorinostat to induce autophagy and apoptosis in small-cell lung cancer, indicating that SAHA can cooperate with other compounds to intensify cell death pathways. Across these studies, related molecular players such as B-cell lymphoma 2, MCL1, FOXO1, mechanistic target of rapamycin kinase, AKT serine/threonine kinase 1, and L-lactate dehydrogenase reflect the broader signaling and metabolic networks often examined alongside HDAC inhibition.